Supplementary Data — Cannabidiol for COVID-19: real-time meta-analysis of 12 studies

October 2026

Cannabidiol COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
00.511.52+
Rotate screen for more detailsIncrease width for more details
← Cannabidiol
reduces risk
Cannabidiol
increases risk →
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.